Index

Note: Page numbers of article titles are in boldface type.

A

Adhesion assays
   in platelet function testing, 178–179
Amegakaryocytosis
   defined, 40
Anemia(s)
   aplastic
      defined, 39
   hematologic
      immune-mediated
         diagnosis of
            flow cytometry in, 60–61
   hemolytic
      in dogs and cats
         erythocyte enzyme deficiencies and, 73–84. See also specific deficiencies and
            Hemolytic anemia, in dogs and cats, erythrocyte enzyme deficiencies and
      of ineffective erythropoiesis
         hepcidin in, 88
   of inflammation
      hepcidin in, 89
iron deficiency
   hepcidin in, 88–89
iron refractory iron deficiency
   hepcidin in, 89–90
   in small animal cancer patients, 124–129
Annexin V binding
   activation-specific changes on platelets in
      flow cytometric techniques in, 183–184
Antiglobulin tests
   technologies for, 49–50
Aperture closure instruments
   in platelet function testing, 175
Aplastic anemia
   defined, 39
Aspirate biopsy
   in bone marrow evaluation, 29–30
ATP release
   in granule disorders evaluation, 184
Automated hematology analyzer
   flow cytometry related to, 60
Bicytopenia
  in small animal cancer patients, 131–132

Biopsy
  in bone marrow evaluation, 25–30. See also Bone marrow, evaluation of, biopsy in
  Birman cat neutrophil granulation anomaly, 165–166
  BLAD. See Bovine leukocyte adhesion deficiency (BLAD)
  BMBT. See Buccal mucosal bleeding time (BMBT)

Bone marrow
  aspiration samples from
    storage of, 30
  evaluation of, 23–55
    biopsy in
      aspirate biopsy, 29–30
      complications of, 30
      core biopsy, 30
      cytologic vs. histologic, 25–27
      equipment for, 28–29
      patient preparation for, 28–29
      procedures, 29–30
      sites of, 25–27
  CME, 31–41. See also Complete marrow evaluation (CME)
  histologic assessment in
    in CME, 34
    indications for, 23–25
    processing in
      technical aspects of, 30–31

Bone marrow disorders
  causes of, 38

Bone marrow films
  assessment of
    in CME, 31–34
    processing and staining of, 31

Bovine leukocyte adhesion deficiency (BLAD), 164

Buccal mucosal bleeding time (BMBT)
  in platelet function testing, 174–175

C

Cancer
  in small animals
    hematologic abnormalities associated with, 123–155. See also specific abnormalities and
    Hematologic abnormalities, in small animal cancer patients
  Canine cyclic hematopoiesis, 166
  Canine leukocyte adhesion deficiency (CLAD), 164–165
  Cat(s)
    c-kit mutations in, 101
    Coombs’ test in
      diagnostic significance of, 47–49. See also Coombs’ test, in dogs and cats,
      diagnostic significance of
DIC in
  laboratory diagnosis of, 189–202. See also Disseminated intravascular coagulation (DIC), in dogs and cats, laboratory diagnosis of
hemolytic anemia in
  erythrocyte enzyme deficiencies and, 73–84. See also Hemolytic anemia, in dogs and cats, erythrocyte enzyme deficiencies and
intestinal lymphoma in
  diagnosis of
    PARR assay in, 106–107
  neutropenia in, 111–122. See also Neutropenia, in dogs and cats
Chediak-Higashi syndrome
  in small animals, 165
Chronic liver disease
  hepcidin in, 89
Circulating blood cell concentrations
  abnormal decreases in
    in small animal cancer patients, 124–132
  abnormal increases in
    in small animal cancer patients, 132–137
Circulation
  abnormal cells in
    in small animal cancer patients, 135–137
C-kit mutation
  in hematologic malignancies in small animals, 98–101
  gastrointestinal stromal cell tumors, 101
  prognosis using conventional therapy related to, 100
  status and response to receptor tyrosine kinase inhibitors, 100
  technical aspects of analysis of, 99–100
  as tumor fingerprint, 100–101
CLAD. See Canine leukocyte adhesion deficiency (CLAD)
Clonality assays
  in hematologic malignancies in small animals, 101–107
  PARR assay
    limitations of, 102–104
    uses of, 104–107
    principles of, 101–102
    technical aspects of, 102
Clot retraction
  in platelet function testing, 179
CME. See Complete marrow evaluation (CME)
Coagulation
  neutrophils in, 163
Coagulopathy(ies)
  in small animal cancer patients, 137–143
Collagen binding
  in platelet function testing, 178
Collie dogs
  gray
    cyclic hematopoiesis of, 166
Complete marrow evaluation (CME), 31–41
  bone marrow film assessment in, 31–34
bone marrow findings from reporting of, 40–41
bone marrow histology assessment in, 34
connective tissue elements in, 34–35
described, 31
hematopoietic elements in, 36
marrow findings interpretation in, 37–40
mononuclear phagocytes and iron in, 36–37
stainable iron in, 34
vasculature in, 35–36
Connective tissue elements in CME, 34–35
Control data in hematologic POCAs for domestic animals management of, 15–19
Coombs’ test in dogs and cats diagnostic significance of, 43–51
test methodology, 43–44
test performance, 45–46
Core biopsy in bone marrow evaluation, 30
Cyclic hematopoiesis of gray Collie dogs, 166
Cytometry flow. See Flow cytometry

D

DIC. See Disseminated intravascular coagulation (DIC)
Disseminated intravascular coagulation (DIC) in dogs and cats laboratory diagnosis of, 189–202
current procedures, 195–198
future directions in, 198–199
past procedures, 194–195
pathophysiology of, 189–192
in small animal cancer patients, 142–143
Disseminated intravascular coagulation (DIC) continuum, 192–194
DNA determination of flow cytometry in, 65–67
Dog(s) Coombs’ test in diagnostic significance of, 46–47. See also Coombs’ test, in dogs and cats, diagnostic significance of DIC in laboratory diagnosis of, 189–202. See also Disseminated intravascular coagulation (DIC), in dogs and cats, laboratory diagnosis of hemolytic anemia in erythrocyte enzyme deficiencies and, 73–84. See also Hemolytic anemia, in dogs and cats, erythrocyte enzyme deficiencies and
neutropenia in, 111–122. See also Neutropenia, in dogs and cats
phosphofructokinase deficiency in
  hemolytic anemia due to, 77–79
Dysplasia
defined, 37
Dysproteinemias
  in small animal cancer patients, 143–144

E
Electron microscopy
  in granule disorders evaluation, 184
Erythrocyte enzyme deficiencies
  in dogs and cats
    differential diagnosis of, 73–75
    hemolytic anemia due to, 73–84. See also specific deficiencies and
Erythrocytosis
  in small animal cancer patients, 132
Erythroid hyperplasia
defined, 37
Erythroid hypoplasia
defined, 39
Erythropoiesis
  ineffective
    anemias of
      hepcidin in, 88
    defined, 39
Erythropoietic signals
  hepcidin in, 87
External quality assurance (EQA) program
  participation in, 20

F
Feline intestinal lymphoma
  diagnosis of
    PARR assay in, 106–107
Femur
  biopsy of
    in bone marrow evaluation, 27
Ferroportin mutations
  hepcidin in, 89
Flow cytometry
  applications of
    in small animal medicine, 3–4, 60–67
      automated hematology analyzer, 60
      DNA content determination, 65–67
      future directions in, 67
      hemolymphoid neoplasia lineage determination, 62–65
      IMHA detection, 60–61
immune disorders diagnosis, 61–62
immunodeficiencies diagnosis, 61–62
thrombopathies diagnosis, 61–62
tumor ploidy determination, 65–67

cell sorting in:
  principles of, 58
detecting properties of cells with light scatter and fluorescence in, 56–58
excitation and collection optics in, 54–56
fluidic system of, 54
instrumentation for:
  basic principles of, 53–54
  components of, 53–54
in platelet function testing, 180–184
  activation-specific changes related to, 181–184
  membrane glycoproteins, 180–181
  principles of, 53–71
sample preparation and processing in, 59–60

Fluidics
  of flow cytometry, 54

G

Gastrointestinal stromal cell tumors
  c-kit mutations in, 101

Glycoprotein(s)
  membrane
    in platelet function testing
      flow cytometry in evaluation of, 180–181

Glycoprotein (GP) IIb-IIIa
  activated
    activation-specific changes on platelets by
      flow cytometric techniques in, 183

Granule disorders
  testing of
    functional and quantitative assays in, 184

Granule membrane proteins
  activation-specific changes on platelets by
    flow cytometric techniques in, 182–183

Granule-secreted proteins
  activation-specific changes on platelets by
    flow cytometric techniques in, 183

Granulocytopenia
  defined, 39

Gray Collie syndrome, 166

H

Hematologic abnormalities
  in small animal cancer patients, 123–155. See also specific abnormalities
    abnormal decreases in circulating blood cell concentrations, 124–132
    abnormal increases in circulating blood cell concentrations, 132–137
anemia, 124–129
bicytopenia, 131–132
cogulopathies, 137–143
described, 123
DIC, 142–143
dysproteinemias, 143–144
erthrocytosis, 132
hypercoagulability, 139–142
hypocoagulability, 138–139
leukocytosis, 134–135
leukopenia, 131
pancytopenia, 131–132
thrombocytopenia, 129–131
thrombocytosis, 133–134
Hematologic anemia
immune-mediated
diagnosis of
flow cytometry in, 60–61
Hematologic malignancies
in small animals
molecular diagnostics of, 97–110
clonality assays in, 101–107. See also Clonality assays, in hematologic malignancies in small animals
mutation detection in individual oncogenes, 98–101
c-kit mutation, 98–101. See also C-kit mutation, in hematologic malignancies in small animals
test categories, 97
Hematology
automated and manual
nonstatistical quality assurance for, 14–15
in-house
statistical quality control in, 19–20
POCAs
for domestic animals, 11–22. See also Point-of-care analyzers (POCAs), hematology, for domestic animals
quality assurance
for domestic animals, 11–22. See also Quality assurance, hematology, for domestic animals
Hematopoiesis
canine cyclic, 166
Hematopoietic elements
in CME, 36
Hemochromatosis
hereditary
hepcidin in, 88
Hemolymphoid neoplasia
lineage of
flow cytometry in determination of, 62–65
Hemolytic anemia
in dogs and cats
erythrocyte enzyme deficiencies and, 73–84
diagnostic tests for, 80
differential diagnosis of, 73–75
phosphofructokinase deficiency, 77–79
pyruvate kinase deficiency, 75–77

Hemosiderosis
defined, 40

Hemostatic system
described, 189

Hepcidin
in anemia of inflammation, 89
in anemias of ineffective erythropoiesis, 88
biological activity of, 87
biology of, 86–88
in chronic liver disease, 89
clinical applications of, 91–92
diagnostic applications of, 91–92
excretion of, 86
in hereditary hemochromatosis, 88
in hypotransferrinemia, 88
increased activity of
disorders associated with, 89–90
in iron deficiency anemia, 88–89
in iron metabolism, 85–96
in iron refractory iron deficiency anemia, 89–90
laboratory evaluation of, 90–91
regulation of expression of, 87–88
in renal disease, 90
resistance to
disorders associated with, 89
serum concentration of, 87–88
structure of, 86
studies in animals, 90
synthesis of, 86
therapeutic applications of, 92

Hereditary hemochromatosis
hepcidin in, 88

Histiocytosis
defined, 40

Humerus
biopsy of
in bone marrow evaluation, 25–26

Hypercoagulability
in small animal cancer patients, 139–142

Hyperplasia(s)
defined, 37

Hypocoagulability
in small animal cancer patients, 138–139

Hypoplasia(s)
defined, 39

Hypotransferrinemia
hepcidin in, 88
Ilium
  biopsy of
    in bone marrow evaluation, 26–27
IMHA. See Immune-mediated hematologic anemia (IMHA)
Immune disorders
  diagnosis of
    flow cytometry in, 61–62
Immune-mediated hematologic anemia (IMHA)
  diagnosis of
    flow cytometry in, 60–61
Immune response
  neutrophils in, 163
Immunodeficiency(ies)
  diagnosis of
    flow cytometry in, 61–62
Impact-R
  in platelet function testing, 178
Impedance technology
  in-house
    for small animal practitioners, 2–3
In-clinic hematology instruments
  automated
    for small animal practitioners, 1–9
      flow cytometric analysis, 3–4
      impedance technology, 2–3
      QBC analysis, 1–2
      selection process, 6–8
      types of, 1–4
      uses of, 4–6
Ineffective erythropoiesis
  defined, 39
Inflammation
  anemia of
    hepcidin in, 89
    hepcidin in, 87–88
    neutrophils in, 163
Intestinal lymphoma
  feline
    diagnosis of
      PARR assay in, 106–107
Iron
  metabolism of
    hepcidin in, 85–96. See also Hepcidin
    regulation of, 86
  mononuclear phagocytes and
    in CME, 36–37
  requirements for, 85
  stainable
    in CME, 34
  uses for, 85–86
Iron deficiency anemia
  hepcidin in, 88–89
iron refractory
  hepcidin in, 89–90
Iron refractory iron deficiency anemia
  hepcidin in, 89–90

L
LaserCyte, 3–4
Leukocytosis
  in small animal cancer patients, 134–135
Leukopenia
  in small animal cancer patients, 131
LIBS. See Ligand-induced binding sites (LIBS)
Ligand-induced binding sites (LIBS)
  activation-specific changes related to flow cytometry techniques in, 182
Liver disease
  chronic
    hepcidin in, 89
Lymphocytosis
  defined, 40
Lymphoma(s)
  feline intestinal
diagnosis of
    PARR assay in, 106–107

M
Malignancy(ies)
  hematologic
    in small animals
      molecular diagnostics of, 97–110. See also Hematologic malignancies, in small animals, molecular diagnostics of
Mastocytosis
  defined, 40
MDS. See Myelodysplastic syndrome (MDS)
MEA. See Multiplate electrical impedance aggregometry (MEA)
Megakaryocytic hyperplasia
  defined, 37
Megakaryocytic hypoplasia
  defined, 39
Megakaryocytopenia
  defined, 39
Mononuclear phagocytes
  in CME, 36–37
Multiplate analyzer
  in platelet function testing, 177–178
Multiplate electrical impedance aggregometry (MEA)
  in platelet function testing, 177–178
Mutation(s)
c-kit. See C-kit mutation
ferroportin
  hepcidin in, 89
in individual oncogenes
  in hematologic malignancies in small animals
detection of, 98–101
Myelodysplastic syndrome (MDS)
defined, 39
Myelofibrosis
defined, 40
Myeloid hyperplasia
defined, 37
Myeloid hypoplasia
defined, 39

N
Necrosis
defined, 40
Neoplasia
defined, 37
  hemolymphoid
  lineage of
    flow cytometry in determination of, 62–65
NETs. See Neutrophil extracellular traps (NETs)
Neutropenia
defined, 112
  in dogs and cats, 111–122
    consequences of, 118–119
    decreased production of, 112–116
    destruction of, 117
    increased use of, 112
    morphology of, 117–118
Neutrophil(s)
described, 111–112, 157
  granules of, 157–158
  recruitment of, 158–160
  in small animals
    function of, 157–171
      in immune response, inflammation, and coagulation, 163
      inherited disorders of, 164–167
        Birman cat neutrophil granulation anomaly, 165–166
        BLAD, 164
        canine cyclic hematopoiesis, 166
        Chediak-Higashi syndrome, 165
        CLAD, 164–165
        Pelger-Huet, 166–167
        intracellular killing, 161–162
microbicidal mechanisms in, 161–163
phagocytosis, 161–162
priming and activation, 161
Neutrophil extracellular traps (NETs), 162–163

O
Oncogenes
mutation detection in, 98–101

P
Pancytopenia
in small animal cancer patients, 131–132
PARR (PCR for Antigen Receptor Rearrangements) assay
limitations of, 102–104
uses of, 104–107
Pelger-Huet, 166–167
Phagocyte(s)
mononuclear
in CME, 36–37
Phagocytosis
neutrophils in, 161–162
Phosphofructokinase deficiency
in dogs
hemolytic anemia due to, 77–79
Plasmacytosis
defined, 40
Platelet(s)
described, 173
functions of, 173
Platelet aggregation assays
in platelet function testing, 179
Platelet aggregometry
in platelet function testing, 179
Platelet function
testing of
adhesion assays in, 178–179
flow cytometry in, 180–184
granule disorders/functional and quantitative assays in, 184
platelet aggregation assays in, 179
in small animal practice, 173–188
whole blood assays in, 174–178
aperture closure instruments in, 175
BMBT, 174–175
Impact-R, 178
MEA, 177–178
PlateletWorks assay, 177
ROTEM, 175–177
Sonoclot Analyzer, 175
TEG, 175–177
VerifyNow, 177
viscoelastic coagulation analyzers, 175–177
Platelet Function Analyzer–100
in platelet function testing, 175
PlateletWorks assay
in platelet function testing, 177
POCAs. See Point-of-care analyzers (POCAs)
Point-of-care analyzers (POCAs)
described, 11–12
hematology
for domestic animals, 11–22
control data in, 15–19
factors influencing, 12–13
minimizing postanalytical error, 20–21
minimizing preanalytical error, 13
personnel training, health, and safety issues, 13
Point-of-care testing (POCT)
defined, 11
Postanalytical error
minimizing of
in hematologic POCAs in veterinary practice, 20–21
Preanalytical error
minimizing of
in hematologic POCAs in veterinary practice, 13
Preleukemia
defined, 39
ProCyte, 3–4
Pure red cell aplasia
defined, 40
Pure white cell aplasia
defined, 40
Pyruvate kinase deficiency
in dogs and cats
hemolytic anemia due to, 75–77
Q
QBC analysis. See Quantitative buffy coat (QBC) analysis
QBC Vet AutoRead, 2–3
Quality assurance
hematology
for domestic animals, 11–22
control data in, 15–19
external programs
participation in, 20
minimizing postanalytical error, 20–21
minimizing preanalytical error, 13
personnel training, health, and safety issues, 13
quality control and, 13–20
nonstatistical
for automated and manual hematology, 14–15
Quality control
  hematology
    for domestic animals
      quality assurance and, 13–20
  statistical
    described, 19–20
Quantitative buffy coat (QBC) analysis
  in-house
    for small animal practitioners, 1–2

R
Receptor-induced binding sites (RIBS)
  activation-specific changes on platelets in
    flow cytometric techniques in, 181
Receptor tyrosine kinase inhibitors
  c-kit mutations status and response to, 100
Renal clearance
  impaired
    hepcidin in management of, 88
Renal disease
  hepcidin in, 90
RIBS. See Receptor-induced binding sites (RIBS)
Rotational thromboelastometry (ROTEM)
  in platelet function testing, 175–177
ROTEM. See Rotational thromboelastometry (ROTEM)

S
Serotonin
  uptake and release of
    in granule disorders evaluation, 184
Sonoclot Analyzer
  in platelet function testing, 175
Stromal cell tumors
  gastrointestinal
    c-kit mutations in, 101

T
TEG. See Thromboelastography (TEG)
Thrombocytopenia
  in small animal cancer patients, 129–131
Thrombocytosis
  in small animal cancer patients, 133–134
Thromboelastography (TEG)
  in platelet function testing, 175–177
Thromboelastometry
  rotational
    in platelet function testing, 175–177
Thrombopathy(ies)
diagnosis of
flow cytometry in, 61–62

Tumor(s)
gastrointestinal stromal cell
c-kit mutations in, 101
ploidy of
flow cytometry in, 65–67

V
Vasculature
assessment of
in CME, 35–36
VerifyNow
in platelet function testing, 177
Viscoelastic coagulation analyzers
in platelet function testing, 175–177
von Willebrand factor (vWF)
function of
in platelet function testing, 178–179
von Willebrand factor (vWF) antigen
in platelet function testing, 178

W
Whole blood assays
in platelet function testing, 174–178